By FOCUS, A Leonine Business
States and producers are now confronting a major reset of federal hemp policy after Congress enacted HR 5371, which amends the existing law to sharply narrow the legal definition of “hemp.” The law writes total tetrahydrocannabinols, including tetrahydrocannabinolic acid (THCA), into the core definition and carves out many hemp-derived cannabinoid products from the “hemp” category altogether. It also creates a distinct “industrial hemp” category for non-cannabinoid uses and directs the FDA to publish detailed lists of naturally occurring cannabinoids, THC-class cannabinoids, and other cannabinoids with similar effects. In practice, HR 5371 puts most intoxicating hemp products, especially chemically converted cannabinoids like delta-8 THC, at risk of falling outside the federal hemp carve-out and back under controlled substance rules. The one-year delayed effective date gives producers and states a limited window to adjust before the new federal framework takes hold.
U.S. Congress Enacts HR 5371 Restricting Intoxicating Hemp Products
Bill: HR 5371
Date Enacted: November 12, 2025
Effective Date: Hemp provisions take effect 365 days from the date of enactment, November 12, 2026
HR 5371 amends existing law to redefine “hemp,” create a separate “industrial hemp” category, and establishes a new federal definition for “hemp-derived cannabinoid products.” It also directs the FDA to quickly publish lists of relevant cannabinoids and additional guidance on what counts as a “container” for enforcement purposes. Key provisions include:
- A revised hemp definition with explicit total THC cap: HR 5371 keeps the existing 0.3 percent delta-9 THC framework but clarifies that “hemp” means Cannabis sativa L. and its parts, including derivatives and cannabinoids, with “total tetrahydrocannabinols” of not more than 0.3 percent on a dry-weight basis. This creates a total-THC standard rather than a delta-9-only interpretation.
- An exclusion of seeds from plants over 0.3 percent THC: The revised hemp definition specifically excludes viable seeds from Cannabis sativa L. plants that would exceed 0.3 percent total tetrahydrocannabinols on a dry-weight basis. This is meant to prevent the use of high-THC genetics in programs that claim hemp status at the seed stage.
- A new definition of “industrial hemp” focused on non-cannabinoid uses: The law defines “industrial hemp” as hemp grown for fiber, stalk, grain, oil, cake, hulls, microgreens and other edible leaf products from low-THC seed.
- A definition of “hemp-derived cannabinoid product”: The act defines “hemp-derived cannabinoid product” as any intermediate or final product derived from hemp (other than industrial hemp) that contains cannabinoids in any form and is intended for human or animal use by inhalation, ingestion, or topical application. It also defines “intermediate hemp-derived cannabinoid product” and “container,” and clarifies that FDA-approved drugs are excluded from this category.
- An exclusion of synthetic and converted cannabinoids from the “hemp” definition: The act expressly excludes from “hemp” any intermediate or final hemp-derived cannabinoid products that contain cannabinoids not capable of being naturally produced by a Cannabis sativa L. plant, or cannabinoids that can be naturally produced but were synthesized or manufactured outside the plant.
- A numeric limits on THC and similar-effect cannabinoids:
- For intermediate products, “hemp” excludes any product with more than 0.3 percent combined total of total tetrahydrocannabinols and any other cannabinoids that have, or are marketed to have, similar effects to THC.
- For final consumer products, “hemp” excludes any product with more than 0.4 milligrams per container of combined total THC and similar-effect cannabinoids. These thresholds are low enough that most intoxicating hemp edibles, vapes, and similar products would no longer qualify as “hemp” at the federal level.
- A limit on selling intermediate products directly to consumers: The act also excludes from “hemp” any intermediate hemp-derived cannabinoid products that are marketed or sold as a final product or directly to an end consumer for personal or household use. This is designed to keep bulk intermediates in the supply chain and out of the retail market, unless they meet the strict final-product limits.
- An FDA 90-day mandate to publish cannabinoid lists: Within 90 days of enactment, the FDA, in consultation with other federal agencies, is required to publish a list of cannabinoids known to be naturally produced by Cannabis sativa L., a list of naturally occurring THC-class cannabinoids and a list of other cannabinoids with similar or marketed-as-similar effects to THC. These lists will be used to interpret how the act’s 0.3 percent and 0.4 milligram thresholds will be enforced.
- A one-year delayed effective date: The hemp definition amendments take effect 365 days after enactment in order to give states, USDA-licensed hemp producers, and hemp-derived product manufacturers a one-year transition period before the new definitions and thresholds are fully enforced.
The purpose of HR 5371 is to reestablish federal clarity on hemp’s legal boundaries, particularly in response to the widespread availability of intoxicating hemp products and inconsistent state approaches.
State-Federal Context
The new federal framework lands on top of a patchwork of state rules that already attempt to manage intoxicating hemp products through potency caps, age limits, or outright bans. HR 5371’s redefinition of hemp, its separation of “industrial hemp” from cannabinoid products, and its hard numeric caps on THC and similar-effect cannabinoids will interact with those state systems by determining what remains “hemp” under federal law and what reverts to controlled-substance treatment. In parallel, the FDA has been tasked with quickly publishing cannabinoid lists and container guidance, which will become a key interpretive tool for both state regulators and industry as they navigate the future of hemp-derived cannabinoids in the wake of HR 5371.
Background
After Congress passed the 2018 Farm Bill, HR 2, which legalized “hemp” and its derivatives so long as products contained no more than 0.3 percent delta-9 THC, a major loophole opened unintentionally. The law measured only delta-9 THC, not total THC or other cannabinoids, and it did not address the chemical conversion of CBD into intoxicating compounds. Because hemp plants produce large amounts of CBD, manufacturers learned they could convert that CBD into delta-8, delta-10, HHC, THC-O, and other psychoactive cannabinoids that technically were not prohibited under the 2018 statutory definition. These products remained federally “legal” so long as the originating plant met the hemp definition. This unintended gap created a nationwide marketplace for intoxicating hemp products, prompting Congress to tighten the definitions in HR 5371.
by Jordan White 11/19/25